Pancreatic Cancer Clinical Trials in Tennessee

Showing 81-100 of 143 trials

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

NCT02947165

To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.

Breast CancerLung CancerHepatocellular Cancer+3 more

Novartis Pharmaceuticals120 participantsStarted Apr 2017

Nashville, Tennessee, United States • Salt Lake City, Utah, United States • Salzburg, Austria +9 more locations

COMPLETEDPhase 229 miles

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

NCT03261947

The purpose of this study is to confirm the safety and tolerability of TAK-931 in a cohort of Western participants with metastatic solid tumors and to evaluate the anti-tumor activity of TAK-931 in participants with metastatic pancreatic cancer, colorectal cancer (CRC), squamous esophageal cancer (sqEC), and squamous non-small-cell lung cancer (sqNSCLC).

Metastatic Pancreatic CancerColorectal CancerEsophageal Neoplasms+1 more

Millennium Pharmaceuticals, Inc.101 participantsStarted Oct 2017

Denver, Colorado, United States • Sarasota, Florida, United States • Minneapolis, Minnesota, United States +7 more locations

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

Pancreatic Cancer Trials in Other Cities

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations

Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer

Vaccine Study for Surgically Resected Pancreatic Cancer

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer

Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery

A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer

Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options

Other Conditions in Tennessee